“Joyce has led our Swords Campus through transition and integration into the successful business entity it is today. She is highly respected by all who work for and with her. I have no doubt SK’s Swords Campus will continue to flourish under Joyce’s leadership, and I am delighted to welcome Joyce formally to the SK pharmteco Executive Management Team”, said Dr Aslam Malik, CEO of SK pharmteco, the parent company of SK biotek Ireland.
“I am delighted to be a part of the growing SK Pharmteco Global CDMO and know our Swords Campus will continue to play a key leadership role. Our Team is excited to play our part in the manufacture of critical APIs for our customers and their patients worldwide” shares Ms. Fitzharris.
Joyce has worked within the Active Pharmaceutical Ingredients (API) business for close to 30 years. She held multiple technical and Quality management positions with increasing levels of responsibility with Bristol Meyers Squibb (BMS) and managed Operational Excellence across several affiliated API sites while with BMS and later at SK biotek Ireland.
Joyce holds a B.Sc. Analytical Science and a M.Sc. Emergency Management from Dublin City University, and a M.Sc. Environmental Protection from Sligo Regional Technical College, Ireland.
We’re delighted that Steve Barr, Vice President Of Business Development, SK pharmteco will be speaking on the “Taking stock: Impact on supply chains in a post Covid world” session at Pharma Integrates on 17th November 2020
About SK Pharmteco
SK pharmteco is the single customer-facing team comprised of SK biotek Ireland, AMPAC Fine Chemicals, SK biotek Korea. Creating substantial market synergies in the API CDMO space by combining highly complementary assets and expertise, this union enables us to provide the highest-quality services to our customers.
